Introduction
Significant progress has been achieved over the past few years demonstrating the potential for adoptive T cell transfer to treat cancer. One of the most promising approaches is the introduction of chimeric antigen receptors (CARs) to redirect T cell specificity with high affinity antibodybased recognition units. 1 CARs are synthetic molecules containing three distinct modules: an extracellular target binding module, a transmembrane module that anchors the molecule into the cell membrane, and an intracellular signaling module that transmits activation signals. show remarkable anti-tumor effects in patients with neuroblastoma, chronic lymphocytic leukemia, non-Hodgkin lymphoma and acute lymphoid leukemia. [6] [7] [8] [9] [10] Over the past decade a new effector CD4 + T helper cell subset that secretes IL-17 was discovered, 11, 12 and it has become clear that T H have been found to be more potent at eradicating melanoma than T H 1 or non-polarized (T H 0) T cells. [13] [14] [15] Importantly, T H 17 cells have considerable plasticity, and can acquire certain type 1 characteristics (such as IFN-γ production) depending on the inflammatory conditions. The ability of T H 17 cells to acquire T H 1 cell-like features appears to be a prerequisite for potent antitumor activity. 13 One obstacle to the use of T H 17 cells for adoptive cell transfer is the identification of robust culture conditions that limit the inherent plasticity of this subset. [16] [17] [18] For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From Two properties of CAR T cells that correlate with potency are the specific lymphocyte subsets that are infused and the signaling domains of the CAR. Pre-clinical studies indicate that cells with extensive proliferative capacity are more potent. [19] [20] [21] In mice adoptive transfer experiments indicate that T H 17 cells have higher in vivo survival and self-renewal capacity than T H 1 polarized cells. 14 In studies using CAR T cells, incorporation of signaling domains from CD28 or from TNF family members CD137 (4-1BB) or CD134 (OX40) has been shown to prevent anergy and enhance antitumor effects. 2, 22 Inducible costimulator (ICOS, also called CD278) is a member of the CD28 family. We have previously shown that ICOS, but not CD28, is necessary for optimal expansion and function of human T H 17 cells. 15 
Materials and Methods

Generation of SS1-CARs and lentivirus production
Mesothelin specific SS1-based CARs containing the TCR-ζ signal-transduction domain alone (ζ) or in combination with the CD28 (28ζ) or the 4-1BB (BBζ) intracellular domains were generated as previously described. 23 The third generation self-inactivating lentival expression vector containing the SS1-ICOSz CAR was generated as described in the SI text. High-titer replicationdefective lentiviral vectors were produced and concentrated as previously described.
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Isolation, Polarization, Transduction and Expansion of T H 17 and T C 17 cells
Blood samples were obtained from the Human Immunology Core of the University of Pennsylvania. The study was conducted in accordance with the Declaration of Helsinki.
Peripheral blood CD4
+ and CD8 + T cells were negatively isolated using RosetteSep Kits (Stem cell Technologies) and cultured under T H 17 conditions as previously described 15 ( Fig. 1 B) . For stimulation, CD4 + and CD8 + T cells were cultured with activating beads coated with antibodies to CD3 (eBioscience, San Diego, CA) and ICOS (Japan Tobacco Inc, Japan and eBioscience) at a 1:3 cell to bead ratio.
Cytokine Production of Restimulated T Cells.
T cells (4 x 10 5 ) were cocultured with 2 x 10 5 K562, K562.meso, or mesothelin-expressing tumor cells and supernatants were harvested 24 hours later. Concentrations of IL-17A, IL17-F, IL-22, IL-2, IFN-γ, TNF-α, IL-10, IL-4 and CCL20 were determined using the DuoSet® ELISA Development Systems (R&DSystems, Minneapolis, MN). Concentrations of IL-21 were determined using Human IL-21 ELISA Ready-SET-Go! Set (eBioscience).
Flow cytometry:
The following conjugated antibodies were purchased from eBioscience: anti-CD161 PE, Ig (PE), anti-CD8 APC, anti-CD4 PerCp-Cy5.5, anti-CD4-PE, anti-CD45 PerCpCy5.5, anti-CD45 APC. Expression of the various SS1 scFv fusion proteins on T cells was detected using biotinylated goat anti-mouse IgG (specific for scFvs of murine origin) from Jackson ImmunoResearch (West Grove, PA). Streptavidin (PE) and streptavidin (APC) were purchased from BD Biosciences. Cells were stained for viability with aqua amine-reactive viability dye (Invitrogen, Frederick, MD) for 30 min at room temperature. Surface staining was performed at 4°C for 30 min in PBS supplemented with 3% FBS. Samples were analyzed in the LSRII flow cytometer using the DiVa software (BD Biosciences, San Jose, CA), and results were evaluated using the FlowJo software (TreeStar, Eugene, OR).
Microarray studies
Redirected T cells from 3 different normal human donors were stimulated with immobilized yeast-derived recombinant mesothelin. 25 Cell pellets were collected and frozen at indicated time points upon antigen recognition. Gene expression levels were determined with GeneChip Human Gene 1.0 ST arrays according to manufacturer's protocols (Affymetrix, Santa Clara, CA).
Description of methods and statistical analysis is included in Supplemental data. (GEO accession number: GSE58867.)
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) for gene lists that were ranked by log2-fold changes were constructed, representing the expression patterns of T H 17 cells expressing three different CARs.
Analysis was performed using a modified R version of the GSEA code provided by the Broad
Institute. In all cases we used a list of 74 T H 17-relevant genes that was previously curated from literature.
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Multidimensional scaling analysis
We performed multidimensional scaling (MDS) analysis on 886 differentially expressed genes among three CARs (P<0.05, t-test) using Euclidean distances, and the R function cmdscale() with parameters set as k=2 dimensions, and eigenvalues=TRUE. x L x W x W, where L is length (longest dimension) and W is width (shortest dimension).
Quantitative gene expression analysis by RT-PCR
Peripheral blood was obtained from retro-orbital bleeding or intracardiac puncture and stained for the presence of human CD45, CD4, and CD8 T cells. After gating on the human CD45 + population, the CD4 + and CD8 + subsets were quantified using TruCount tubes (BD Biosciences).
All experiments were performed in a blinded, randomized fashion. 
Results
Construction and expression of ICOS-based CARs
The CAR constructs used in this study contain the SS1 scFv that recognizes human mesothelin ( Fig. 1 A) . The scFv was fused to the TCR-ζ signal transduction domain with the CD28, 4-1BB
or ICOS signaling domains in tandem. As negative control for signal transduction, we used a chimeric receptor containing a truncated form of the TCR-ζ intracellular domain (delζ). CD4 + T cells were activated with beads coated with anti-CD3 and anti-ICOS antibodies in the presence of T H 17 polarizing cytokines, transduced with lentiviral vectors encoding SS1-based chimeric receptors, and expanded ( Fig. 1 B) . For all functional assays, T cell cultures were normalized for equivalent CAR expression by addition of mock transduced T cells as required. The surface expression of all CAR constructs was similar ( Fig. 1 C) .
In vitro function of ICOS-based CAR cells
One of the functional hallmarks of T H 17 cells is the production of large amounts of IL-17A, IL-17F and IL-22. To test the cytokine response of the mesothelin redirected T cells, we cocultured them with tumor cells that expressed mesothelin and quantified the concentrations of cytokines in the supernatants by ELISA (Fig 2 A) . We observed a significant enhancement of IL-17A, IL17-F 
Surface phenotype of ICOS-based CAR T cells
Human T H 17 cells can be identified by their surface expression of the lectin-like receptor CD161/NKRP1A, a marker of all human IL-17-producing T-cell subsets. 15, 16 Therefore, we measured the frequency of CD161 + T cells after surrogate antigen recognition. We observed a progressive enrichment of CD161 + cells in the ζ and ICOSζ CAR cultures. In contrast, cells expressing CD161 were not enriched in the cultures containing BBζ or 28ζ CAR T cells (Fig. 3 A). This enrichment was reproducible as it was observed in ICOSζ CAR expressing T cells from 12 healthy donors (Figure 3 B ). In contrast to T H 17 cytokine production, no differences in CD161 expression were observed between cells redirected with ζ or ICOSζ CARs (Fig. 3 C) (Fig. 3 D) .
Transcriptional signature of T cells expressing ICOS-based CARs
The enhanced expression of CD161 together with the selective secretion of IL-17 suggests that the ICOSζ CAR can be used to maintain a T H 17 cell phenotype. To fully characterize the spectrum of Th17 related markers in our cells, we next used gene expression analysis to perform an unbiased characterization of the effects of the CAR signaling domains on T cell activation after antigen recognition. Redirected CD4 + cells from three healthy donors were restimulated with surrogate antigen using immobilized recombinant mesothelin-Fc and gene expression levels Our results stimulating T cells through the CAR signaling domains are similar to previous studies after ICOS and CD28 costimulation through the endogenous receptors. 27 We identified only 2 genes that were markedly up regulated by CD28ζ-expressing T cells, compared to both ICOSζ and BBζ CAR T cells: IL-2 and IL-8 ( The T H 17 developmental regulatory network in the mouse has been recently characterized 26 , and it was shown that a gene's involvement in T H 17 function can be predicted using a network-based "KCRI" score 26 . This score quantifies the extent to which each gene is regulated by five T H 17 core transcription factors (TFs): Stat3, Batf, Irf4, Maf, and Rorc. Using this network resource, we tested whether the six uncharacterized genes we identified were regulated by the five core T H 17
TFs. We found that Ncs1 was significantly upregulated in T H 17 cells compared to T H 0 cells, and ranked 46 out of more than 22,000 tested genes for T H 17 function based on the "KCRI" scoring 
CD4
+ cells redirected with ICOSζ showed a T H 17 core molecular signature with a T H 1 bias
We next performed gene set enrichment analysis (GSEA) of the microarray data obtained using cells at 4 hours following antigen recognition (Fig. 5 A) . We observed a nonrandom distribution (Fig. 5 B-C) . Notably, they also overexpressed some T H 1-related genes, including Ifnγ, Tnfα and Tbx21 (T-bet) (Fig. 5 B, D) . Importantly, ICOS signaling in T H 17 cells did not induce the expression of T reg -or T H 2-related genes, with the exception of Il13 (Fig. 5 B) . Also, contrary to cytokine and transcription factor expression, signaling through CAR did not induce significant changes in expression of most cell surface markers, including Ccr6, Ccr4 and Ccr10 (Fig S4 A) . Collectively, these results suggest that ICOS-based CARs can sustain T H 17 function with a T H 1 bias.
For
Comparison of antitumor efficacy of T H 17/T H 1 polarized T cells expressing CD28, 4-1BB and ICOS based CARs
We next analyzed the antitumor activity of retargeted T H 17 cells. For this experiment, in addition to redirected T H 17 cells we also redirected T C 17 cells (CD8 + T cells cultured under T H 17 polarizing conditions). 28 Both T H 17 and T C 17 redirected cells efficiently lysed mesothelioma (M108) tumor cells, and no differences in cytotoxicity were observed between CAR signaling domains ( Fig. 6 A) . T C 17 cells secreted robust amounts of IFN-γ following antigen recognition, although IL-17 secretion was not detected ( Figure S5) . Next, the antitumor activity of mixed redirected T H 17 and T C 17 cells was analyzed in NSG mice bearing M108 tumors ( Fig. 6B-C) . A potent antitumor effect was observed in all groups treated with mesothelin-specific CAR T cells.
T cells redirected with BBζ showed a relatively slow tumor decline, with all mice showing significant tumor shrinkage after treatment. 28ζ and ICOSζ treatments showed a more rapid tumor decline, leading to tumor eradication in most mice ( Fig. 6B and S6 ). Treated mice were sacrificed on day 51 after T cell injection as they developed xenogeneic graft versus host disease, and mice treated with the ICOSζ CAR T cells had the most severe GVHD (Fig. S7) . We have previously shown that this tumor does not regress following injection of non-gene modified allogeneic T cells 29 .
CAR T H 17 cells reprogramed with ICOS endodomains have long-lived persistence in vivo
Long-term persistence of adoptively transferred T cells correlates with antitumor effects in clinical trials. 30, 31 Because it has been shown that natural T H 17 cells are long lived in vivo, 14 we next sought to assess the in vivo persistence of CAR-modified T H 17 and T C 17 cells in the peripheral blood of treated mice (Fig. 7 A-B) . The average number of CD4 + T cells per µl of blood and per spleen at the time of sacrifice (day 51) was higher in mice treated with ICOSζ-based CARs, when compared with 28ζ and BBζ groups. Of note, T H 17 cells redirected with ICOS also showed a higher frequency of CD161 + cells, correlating with in vitro results (Fig. 7 C) .
CD8
+ T cells redirected with BBζ persisted better, although differences were not significant (Fig.   7 A) .
To extend these results, we performed a similar experiment with NSG mice bearing non-small cell lung tumors. In order to confirm that T cell persistence was due to tumor recognition, and not to recognition of xenoantigens by the endogenous TCR of these cells, this experiment was done in duplicate using mice with or without tumors (empty mice). T H 17 cells redirected with ICOSζ showed an increased in vivo expansion and persistence that was significantly greater than 28ζ and BBζ groups. Importantly, ICOSζ T cell expansion was dependent on tumor antigen encounter, as empty mice showed significantly fewer ICOSζ cells compared to mice with tumors ( Fig. 7 D) 
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limitation of the present studies is that we do not yet know whether this will be predictive of the results after CAR T cell transfer to patients, and therefore a future clinical trial will be required to test these principles.
To our knowledge our findings are the first to demonstrate that the expression of selected CAR endodomains can program T cells for their subsequent differentiation fates and effector functions.
The balance of Tregs to effector T cells is an important biomarker for the outcome of many immunotherapies, 41 and the ability of ICOS to limit IL-2 secretion may be an important feature in improving this ratio. The observation that CAR T cells bearing ICOS signaling domains have enhanced survival after adoptive transfer provides the rationale to test this concept in human trials in the setting of solid tumors and non-lymphoid hematologic malignancies, where improved persistence of CAR T cells remains as an unmet medical need.
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